REGULATORY
Re-Priced Unprofitable Products Subject to Unit Price-Based Trades for 2 Years: MHLW
The Ministry of Health, Labor and Welfare (MHLW) on March 7 issued a new Q&A guide for its Guidelines for the Improvement of Commercial Transaction Practices of Ethical Drugs, which was revised in March 2024. The revised guidelines specify that…
To read the full story
Related Article
- Japan’s Revised Drug Distribution Guidelines Take Effect
March 4, 2024
REGULATORY
- Japan Panel Seeks Easing of Rules on Radiopharma Research Samples
June 16, 2026
- LDP Team Reviews Draft Industry Cluster Plans for Radiopharma, Blood Products
June 16, 2026
- DPP Calls for End to Off-Year Drug Price Cuts, Chuikyo Reform
June 15, 2026
- Pharma Wages Multi-Front Lobbying amid Push for Leaner Honebuto
June 12, 2026
- Many Approved AGs Remain Unlisted Despite Final Pre-Reform Opportunity
June 12, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





